MUMBAI, April 6, 2015 /PRNewswire/ --
Diabetes market is a rapidly growing segment with numerous products at different stages of clinical pipeline and others at different phases of industry life cycle. Disease incidences are escalating rapidly across the globe due to which high unmet demand has been created and pharmaceutical companies are trying to provide efficient medical care to patients. Large patient base and superior technology are some important factors responsible for continuous growth of this market segment across the globe. Significant investments in research and development segment could also be attributed as the main reason behind its growth. As a result, several innovative products are under investigation which would be introduced in market after passing pre described clinical end points and criteria set by medical regulatory authorities. Number of diabetes drugs for treatment is increasing every year due to which their market shares are expected to increase further in coming years.
Diabetes drug delivery is a mature field which provides lots of opportunities to the pharmaceutical companies to market their products. Innovation seems to be the key to success because it is quite mature and without novel functionality it doesn't seem meaningful to enter in such a competitive market segment. Increased investments in research and development segment are expected to introduce competitive products at cost effective prices in short time. It shows that the diabetes drug market segment would be filled with innovative products that would be able to offer better diabetes management to patients. In this way, it could be expected that this market would be able to grow several folds, generate significant revenues and prevent morbidity caused by diabetes.
To order this report and request for sample page:
https://www.bharatbook.com/drugs-market-research-reports-646382/global-diabetes-drug-pipeline-insight.html
Several molecules belonging to different classes like carbohydrate digestion inhibitors, sulphonyl urea, insulin sensitizers and others are being screened for their effects on diabetes. They have to prove their candidature by providing better safety and efficacy profiles than existing diabetes drugs. Rigorous clinical trials would be required to prove their pharmacological worthiness for effectively treating diabetes patients. These molecules are known to have cytotoxicity due to which they may have side effects but by modulating its design such problems could be overcome by investigators. On the other hand, these molecules are easy to produce and offer higher cost effectiveness due to which pharmaceutical companies have become interested in their research and development. In coming years, more molecules of these types are expected to enter in global market which would be affordable by large number of patients belonging to different socio-economic groups.
Besides screening of novel molecules, emphasis on discovering different pathways have been given by investigators for developing diabetes drugs with higher safety and efficacy profiles. Insulin pathway is one of the most studied pathways that have been widely targeted by investigators to maintain blood glucose levels. Diabetes drugs that target cellular receptors have been made which works at molecular levels because they have higher control over insulin regulation. Some drug molecules increase the glucose uptake in cells to decrease blood glucose levels. On the other hand, there are diabetes drugs that act on the gastrointestinal tract and prevent the carbohydrate digestion in the body. Investigators have developed many methods to control diabetes and several innovative mechanisms are being studied to come forth with better products. As a result, more products will be launched due to which their market penetration is expected to increase in coming years.
Diabetes Indication in Report:
- Diabetic Neuropathies
- Diabetic Nephropathies
- Diabetes Mellitus
- Type 1 Diabetes Mellitus
- Type 2 Diabetes Mellitus
- Diabetic Foot Ulcer
- Diabetic Macular Oedema
- Diabetic Gastroparesis
- Diabetic Retinopathy
- Diabetes Insipidus
- Prediabetic State
Report Highlight:
- Global Diabetes Drug Market Overview
- Global Diabetic Drug Clinical Pipeline by Company & Phase
- Global Diabetic Drug Clinical Pipeline: 817 Drugs
- Majority in Preclinical Phase: 205 Drugs
- Type 2 Diabetes Mellitus Drugs in Pipeline: 380 Drugs
- Type 1 Diabetes Mellitus Drugs in Pipeline: 79 Drugs
- Diabetic Nephropathies Drugs in Pipeline: 41 Drugs
- Marketed Diabetic Drugs: 99 Drugs
Table of Content
1. Introduction to Diabetes
2. Diabetes Drug Mechanism
3. Global Diabetes Drug Market Overview
- Current Market Scenario
- Global Diabetes Drug Pipeline Overview
4. Global Diabetes Drug Market Dynamics
- Favorable Market Parameters
- Development & Commercialization Challenges
5. Global Diabetes Drug Market Future Prospects
6. Diabetic Neuropathies Drug Clinical Pipeline by Company & Phase
- Research to till Registered
- Marketed Drug Clinical Insight
7. Diabetic Nephropathies Drug Clinical Pipeline by Company & Phase
- Research to till Registered
- Marketed Drug Clinical Insight
8. Diabetes Mellitus Drug Clinical Pipeline by Company & Phase
- Phase Research to till Registered
- Marketed Drug Clinical Insight
9. Type 1 Diabetes Mellitus Drug Clinical Pipeline by Company & Phase
- Research to till Registered
- Marketed Drug Clinical Insight
10. Type 2 Diabetes Mellitus Drug Clinical Pipeline by Company & Phase
- Research to till Registered
- Marketed Drug Clinical Insight
11. Diabetic Foot Ulcer Drug Clinical Pipeline by Company & Phase
- Research to till Phase-III
- Marketed Drug Clinical Insight
12. Diabetic Macular Oedema Drug Clinical Pipeline by Company & Phase
- Research to till Registered
- Marketed Drug Clinical Insight
13. Diabetic Gastroparesis Drug Clinical Pipeline by Company & Phase
- Preclinical to till Phase-III
- Marketed Drug Clinical Insight
14. Diabetic Retinopathy Drug Clinical Pipeline by Company & Phase
- Research to till Phase-III
15. Prediabetic State Drug Clinical Pipeline by Company & Phase
- Phase-II
16. Diabetes Drug Clinical Pipeline by Company & Phase
- Research to till Registered
- Marketed Drug Clinical Insight
17. Competitive Landscape
- AstraZeneca
- Boehringer Ingelheim
- Eli Lily
- GalaxoSmithKline
- Johnson & Johnson
- MannKind Corporation
- Merck
- Novartis
- Pfizer
- Sanofi
Related Reports
- 2015 Market Research Report on Global Diabetes Drugs Industry
- Incretin-Based Drugs: Markets for Diabetes Therapies and Developing Treatments
- U.S. Market for Diabetes Monitoring, Treatment and Drug Delivery 2014
- Transdermal Drug Delivery Partnering 2010-2015
About Bharat Book Bureau
Bharat Book Bureau is the leading market research information aggregator that provides market research reports, industry analysis, company profiles, business reports, country reports, newsletters and online databases. Our clients include Corporate, Consulting firms, and Academic Institutions and Government departments across the globe. Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. The market research reports we provide, help global companies examine the different markets before setting up a business or expanding into different countries across the world. They give a complete perspective on the current market scenario, trends, segments and future outlook.
Contact Details:
Poonam
Bharat Book Bureau
India: +91-22-27810772, 27810773
Blog: https://www.bharatbook.com/blog/
W: https://www.bharatbook.com/
E: poonam@bharatbook.com
SOURCE Bharat Book Bureau
